ECSP11010825A - Dabigatrán para la cateterización cardiaca intervencionista percutanea. - Google Patents

Dabigatrán para la cateterización cardiaca intervencionista percutanea.

Info

Publication number
ECSP11010825A
ECSP11010825A EC2011010825A ECSP11010825A ECSP11010825A EC SP11010825 A ECSP11010825 A EC SP11010825A EC 2011010825 A EC2011010825 A EC 2011010825A EC SP11010825 A ECSP11010825 A EC SP11010825A EC SP11010825 A ECSP11010825 A EC SP11010825A
Authority
EC
Ecuador
Prior art keywords
dabigatran
cathetering
interventional cardiac
percutaneous interventional
percutaneous
Prior art date
Application number
EC2011010825A
Other languages
English (en)
Spanish (es)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP11010825A publication Critical patent/ECSP11010825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
EC2011010825A 2008-08-19 2011-02-11 Dabigatrán para la cateterización cardiaca intervencionista percutanea. ECSP11010825A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19

Publications (1)

Publication Number Publication Date
ECSP11010825A true ECSP11010825A (es) 2011-03-31

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010825A ECSP11010825A (es) 2008-08-19 2011-02-11 Dabigatrán para la cateterización cardiaca intervencionista percutanea.

Country Status (19)

Country Link
US (1) US20110301201A1 (enExample)
EP (1) EP2328580A1 (enExample)
JP (1) JP2012500245A (enExample)
KR (1) KR20110044230A (enExample)
CN (1) CN102123707A (enExample)
AR (1) AR073077A1 (enExample)
AU (1) AU2009284217A1 (enExample)
BR (1) BRPI0917507A2 (enExample)
CA (1) CA2734794A1 (enExample)
CL (1) CL2011000361A1 (enExample)
CO (1) CO6290686A2 (enExample)
EA (1) EA201100358A1 (enExample)
EC (1) ECSP11010825A (enExample)
IL (1) IL210005A0 (enExample)
MA (1) MA32563B1 (enExample)
MX (1) MX2011001612A (enExample)
NZ (1) NZ591108A (enExample)
TW (1) TW201022235A (enExample)
WO (1) WO2010020602A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
IN2015DN02601A (enExample) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485094B2 (de) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
JP2008517974A (ja) * 2004-10-25 2008-05-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
KR20110044230A (ko) 2011-04-28
AU2009284217A1 (en) 2010-02-25
AR073077A1 (es) 2010-10-13
JP2012500245A (ja) 2012-01-05
MA32563B1 (fr) 2011-08-01
TW201022235A (en) 2010-06-16
IL210005A0 (en) 2011-02-28
WO2010020602A1 (en) 2010-02-25
CL2011000361A1 (es) 2011-06-17
EA201100358A1 (ru) 2011-10-31
MX2011001612A (es) 2011-03-04
BRPI0917507A2 (pt) 2015-11-17
EP2328580A1 (en) 2011-06-08
NZ591108A (en) 2012-11-30
CA2734794A1 (en) 2010-02-25
CN102123707A (zh) 2011-07-13
US20110301201A1 (en) 2011-12-08
CO6290686A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
CO6290686A2 (es) Dabigatrán para la cateterización cardiaca intervencionista percutánea
CL2019001993A1 (es) Inhibidores selectivos de jak1.
GT201400196A (es) Compuestos de heterociclilo
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
JO3187B1 (ar) (4-(8- ميثوكسي بروبان -2-يل)-2-(تترا هيدرو - 2h - بيران-4-يل)- 1h - ايميدازو [ 4, 5- c ] كوينولين -7-يل)-3, 5- داي ميثيل ايزوكسازول واستخدامه كمثبط نطاق برومو
UY32203A (es) Amino pirimidinas y su uso en terapia
CR20160099A (es) Formulación de inhibidores de la syk
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
DOP2009000257A (es) Inhibidores de cinasa p70 s6
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
CR20130239A (es) Compuestos de triazolopiridina
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
MX2015012386A (es) Inhibidores de la cinasa cdk9.
AR082660A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias
UY31839A (es) Compuestos
AR063027A1 (es) Derivados de sulfonamida
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.